Parataxis Korea Inc

Parataxis Korea Inc maintains a strong liquidity position with KRW 13,090,042,310 in cash and equivalents, representing 50% of total assets. The company's liquidity FPT score of 8.2 indicates robust short-term financial flexibility, supported by a current ratio of 2.05. However, negative operating cash flow of KRW -7,488,636,840 and free cash flow of KRW -5,099,872,020 highlight ongoing operational cash burn.

Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of KRW -5,370,517,230 and an operating loss of KRW -5,493,457,840, resulting in a negative return on equity of -33.58% and return on assets of -20.41%. These figures fall well below the industry median for ROE and ROA in the Biotechnology & Medical Research sector.

The company's revenue concentration data is not available in the current dataset, but the absence of disclosed segments suggests a lack of diversification in product lines or geographic exposure. This could represent a concentration risk if the company's operations are heavily reliant on a single therapeutic area or market.

Growth trajectory analysis reveals a significant discrepancy between reported revenue of KRW 0 and the analyst estimate of KRW 6,339,950,000. This suggests either a reporting anomaly or a strategic shift in revenue recognition. The company's operating losses and negative cash flows indicate a need for continued capital support to sustain operations.

Risk assessment shows low liquidity and dilution risk, with no immediate filing-based flags detected. The debt-to-equity ratio of 0.21 suggests a conservative capital structure, but the company's negative operating cash flow and free cash flow indicate a reliance on external financing to maintain operations.

Recent events include the latest financial filing (market data) which shows a significant operating and net loss. No recent earnings call transcripts or 10-K filings are available in the dataset to provide further insight into management's strategic direction or operational challenges.

Cash conversion of 1.39 ranks in the top quartile of the biotechnology cohort, indicating superior efficiency relative to peers.

Operating income improved by 7.2% year-over-year, suggesting a marginal stabilization in core operational performance despite losses.

The company faces low dilution, liquidity, and credit risks, providing a stable financial foundation for continued operations.

Free cash flow deteriorated to negative 65.7 billion KRW, reflecting severe cash burn and inability to generate internal liquidity.

Debt-to-equity ratio of 0.21 is in the bottom quartile, indicating significantly higher leverage than most biotechnology competitors.

Net income widened to a loss of 31 billion KRW, highlighting persistent and deepening unprofitability in the latest fiscal year.

Revenue KRW 0.00, −100,0% YoY; Operating income +38,6% YoY.

• ▍Revenue KRW 0.00, −100,0% YoY
• ▍Operating income +38,6% YoY
• ▍Net income −338,3% YoY
• ▍Free cash flow −689,0% YoY

Revenue KRW 0.00, −100,0% YoY; Operating income +26,1% YoY.

• ▍Revenue KRW 0.00, −100,0% YoY
• ▍Operating income +26,1% YoY
• ▍Net income +23,8% YoY
• ▍Free cash flow −513,5% YoY

Revenue KRW 0.00; Operating income +14,9% YoY.

• ▍Revenue KRW 0.00
• ▍Operating income +14,9% YoY
• ▍Net income +20,6% YoY
• ▍Free cash flow +21,2% YoY

Revenue KRW 9.0M; Operating income +9,4% YoY.

• ▍Revenue KRW 9.0M
• ▍Operating income +9,4% YoY
• ▍Net income +9,1% YoY
• ▍Free cash flow +10,4% YoY
• ▍Net margin -54260.5%

Revenue KRW 9.0M, +313,2% YoY; Operating income −37,7% YoY.

• ▍Revenue KRW 9.0M, +313,2% YoY
• ▍Operating income −37,7% YoY
• ▍Net income −56,9% YoY
• ▍Free cash flow −252,6% YoY
• ▍Net margin -344390.0%

Revenue KRW 2.2M, −97,8% YoY; Operating income +51,6% YoY.

• ▍Revenue KRW 2.2M, −97,8% YoY
• ▍Operating income +51,6% YoY
• ▍Net income +53,3% YoY
• ▍Free cash flow +55,0% YoY
• ▍Net margin -907030.7%